We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients.
- Authors
Sedighi, Behnaz; Shafiei, Kaveh; Azizpour, Iman
- Abstract
Topiramate is an approved and effective drug in migraine prophylaxis. Paresthesia is the most commonly reported side effect. The primary objective of this study was to compare the frequency of topiramate-induced paresthesia in migraine headache to epileptic patients. Patients with migraine without aura and epilepsy were enrolled in this observational study. All cases were interviewed by telephone about their history of paresthesia. Confounding factors were controlled through logistic regression. The odds ratio of developing topiramate-induced paresthesia in migraine compared to epilepsy patients was 3.4. Three factors were independent contributors to developing topiramate-induced paresthesia: female sex (odds ratio 2.1), topiramate dosage (odds ratio 0.3) and duration of therapy. Our findings indicate an independent association between migraine and development of paresthesia. Migraineurs were more likely than epileptic patients to report paresthesia as topiramate adverse effects. Female sex, treatment duration and topiramate dosage contribute significantly to subsequent development of paresthesia.
- Subjects
TOPIRAMATE; PARESTHESIA; PEOPLE with epilepsy; MIGRAINE; LOGISTIC regression analysis; TREATMENT duration; DRUG side effects; SCIENTIFIC observation; DRUG therapy; CENTRAL nervous system; DRUGS; EPILEPSY; FRUCTOSE; ODDS ratio; THERAPEUTICS
- Publication
Neurological Sciences, 2016, Vol 37, Issue 4, p585
- ISSN
1590-1874
- Publication type
journal article
- DOI
10.1007/s10072-015-2458-9